liver disease

Gilead
Biotech

Gilead pays J&J $320M to exit licensing deal for seladelpar

With Gilead on the verge of an FDA decision for seladelpar, it has paid J&J $320M to exit an 18-year-old licensing agreement on the drug.
Kevin Dunleavy Aug 9, 2024 10:30am
Liver

Calliditas' rethought liver disease trial hits primary endpoint

Jul 26, 2024 5:32am
Wall Street IPO initial public offering markets shares stock

Chemomab trumpets liver disease win, but investors retreat

Jul 25, 2024 9:32am
money funding financing bank

VC firm that took NGM private oversees biotech’s $122M series A

Jul 17, 2024 7:42am
pinpoint point arrow target hit dart bullseye

GSK signs AI pact with Ochre to pinpoint source of liver disease

Jun 12, 2024 9:25am
Liver

Gilead shows $4.3B liver drug improves outcomes out to 2 years

Jun 5, 2024 7:33am